Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 22, 2014

View Archived Issues

Novel pan tyrosine kinase receptor inhibitor identified for the treatment of cancer

RXi Pharmaceuticals updates on phase II program of RXI-109 in scar recurrence prevention

Report of phase I evaluation of a STAT3 ASO for hepatocellular carcinoma

Takeda describes PDE10A inhibitor TAK-063

Phase I study initiated for ProMetic IV plasminogen

SOV Therapeutics' oral testosterone undecanoate meets phase IIb study endpoints

Pfizer starts phase II trial of anti-myostatin antibody in DMD

Further phase III data reveal efficacy of LCZ-696 in hypertension and heart failure

Bayer presents novel TTK inhibitors for cancer

NESP approved for anemia with myelodysplastic syndromes in Japan

Kyowa Hakko Kirin receives additional indication approval for Poteligeo in Japan

Prima BioMed completes acquisition of Immutep

Kadcyla fails to show superiority to Herceptin plus taxane therapy in untreated breast cancer

Polaris' ADI-PEG20 receives E.U. orphan drug status for MPM

Researchers report phase I results on taselisib in breast cancer

Medeia Therapeutics discloses new cytoprotectants

Johns Hopkins University patents novel aptamers for sickle cell anemia

HCV treatment designed by French and U.S. organizations

European orphan drug designation for Halozyme's PEGPH-20 in pancreatic cancer

FDA approves Lynparza, and companion diagnostic, for germline BRCA-mutated advanced ovarian cancer

EMA committee recommends approval of Xadago to treat mid- to late-stage Parkinson's disease

CHMP backs approval of Orexigen's naltrexone/bupropion for weight management

U.S. approval for Cubist's ceftolozane/tazobactam for cUTI and cIAI

FDA approves Rapivab for acute uncomplicated influenza

Intravenous administration of Erwinaze obtains U.S. approval

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...